These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 33386466)

  • 21. γδ T-APCs: a novel tool for immunotherapy?
    Moser B; Eberl M
    Cell Mol Life Sci; 2011 Jul; 68(14):2443-52. PubMed ID: 21573785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy.
    Fowler DW; Copier J; Wilson N; Dalgleish AG; Bodman-Smith MD
    Cancer Immunol Immunother; 2012 Apr; 61(4):535-47. PubMed ID: 22002242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential approaches for more successful dendritic cell-based immunotherapy.
    Chiang CL; Balint K; Coukos G; Kandalaft LE
    Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.
    Nussbaumer O; Gruenbacher G; Gander H; Thurnher M
    Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic Cells and Cancer Immunity.
    Gardner A; Ruffell B
    Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human and murine memory γδ T cells: Evidence for acquired immune memory in bacterial and viral infections and autoimmunity.
    Comeau K; Paradis P; Schiffrin EL
    Cell Immunol; 2020 Nov; 357():104217. PubMed ID: 32979762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
    Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
    Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for
    Huber A; Dammeijer F; Aerts JGJV; Vroman H
    Front Immunol; 2018; 9():2804. PubMed ID: 30559743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS; Klein B
    Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
    Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.
    Anguille S; Lion E; Van den Bergh J; Van Acker HH; Willemen Y; Smits EL; Van Tendeloo VF; Berneman ZN
    Hum Vaccin Immunother; 2013 Sep; 9(9):1956-61. PubMed ID: 23778748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
    Martinet L; Poupot R; Fournié JJ
    Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
    Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
    Front Immunol; 2018; 9():2481. PubMed ID: 30455687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing γδ T cells in anticancer immunotherapy.
    Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
    Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
    Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S
    J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of Human Vδ2
    Cooper AJR; Lalor SJ; McLoughlin RM
    J Immunol; 2020 Aug; 205(4):1039-1049. PubMed ID: 32651220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell-based immunotherapy: a basic review and recent advances.
    Constantino J; Gomes C; Falcão A; Neves BM; Cruz MT
    Immunol Res; 2017 Aug; 65(4):798-810. PubMed ID: 28660480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells.
    Saito A; Narita M; Yokoyama A; Watanabe N; Tochiki N; Satoh N; Takizawa J; Furukawa T; Toba K; Fuse I; Aizawa Y; Shinada S; Takahashi M
    J Clin Exp Hematop; 2007 Nov; 47(2):61-72. PubMed ID: 18040145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.